Search research articles
Contact Us
Filters
Showing results (241-250 of 269) with videos related to
Page
of 27
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 26, 2020
CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma
Peter Herhaus, Jana Lipkova, Felicitas Lammer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 5, 2023
Chemokine Receptor PET/CT Provides Relevant Staging and Management Changes in Marginal Zone Lymphoma
Johannes Duell, Andreas K Buck, Philipp E Hartrampf, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 14, 2015
First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease
Ken Herrmann, Margret Schottelius, Constantin Lapa, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 4, 2022
Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms Using <sup>68</sup>Ga-Pentixafor PET
Andreas K Buck, Alexander Haug, Niklas Dreher, et al.
Thyroid : Official Journal of the American Thyroid Association
|
August 18, 2021
Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer
Viktoria Florentine Koehler, Elke Berg, Pia Adam, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 3, 2025
Multicentric Matched-Pair Analysis of Long-Term Hematotoxicity of Peptide Receptor Radionuclide Therapy in Patients Postsplenectomy
Lisa Steinhelfer, Friederike Jungmann, Lukas Endroes, et al.
Theranostics
|
January 2, 2018
Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics
Stefan Habringer, Constantin Lapa, Peter Herhaus, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 5, 2026
Initial Clinical Experience with [<sup>177</sup>Lu]Lu-RTX-2358 Radiopharmaceutical Therapy Targeting Fibroblast Activation Protein: Biodistribution, Pharmacokinetics, and Dosimetry
Lisa Glantschnig, Johanna S Enke, Bradley W Schuller, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
June 11, 2026
Effects of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing [<sup>177</sup>Lu]Lu-PSMA-617 or [<sup>177</sup>Lu]Lu-PSMA-I&T therapy: dosimetry results
Josef Zahner, Astrid Delker, Zachary Ells, et al.
Theranostics
|
August 2, 2019
Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?
Leo Rasche, Manoj Kumar, Grant Gershner, et al.
Page
of 27
Search research articles
Search
Showing results (241-250 of 269) with videos related to
Sort By:
Page
of 27
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 26, 2020
CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma
Peter Herhaus, Jana Lipkova, Felicitas Lammer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 5, 2023
Chemokine Receptor PET/CT Provides Relevant Staging and Management Changes in Marginal Zone Lymphoma
Johannes Duell, Andreas K Buck, Philipp E Hartrampf, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 14, 2015
First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease
Ken Herrmann, Margret Schottelius, Constantin Lapa, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 4, 2022
Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms Using <sup>68</sup>Ga-Pentixafor PET
Andreas K Buck, Alexander Haug, Niklas Dreher, et al.
Thyroid : Official Journal of the American Thyroid Association
|
August 18, 2021
Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer
Viktoria Florentine Koehler, Elke Berg, Pia Adam, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 3, 2025
Multicentric Matched-Pair Analysis of Long-Term Hematotoxicity of Peptide Receptor Radionuclide Therapy in Patients Postsplenectomy
Lisa Steinhelfer, Friederike Jungmann, Lukas Endroes, et al.
Theranostics
|
January 2, 2018
Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics
Stefan Habringer, Constantin Lapa, Peter Herhaus, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 5, 2026
Initial Clinical Experience with [<sup>177</sup>Lu]Lu-RTX-2358 Radiopharmaceutical Therapy Targeting Fibroblast Activation Protein: Biodistribution, Pharmacokinetics, and Dosimetry
Lisa Glantschnig, Johanna S Enke, Bradley W Schuller, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
June 11, 2026
Effects of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing [<sup>177</sup>Lu]Lu-PSMA-617 or [<sup>177</sup>Lu]Lu-PSMA-I&T therapy: dosimetry results
Josef Zahner, Astrid Delker, Zachary Ells, et al.
Theranostics
|
August 2, 2019
Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?
Leo Rasche, Manoj Kumar, Grant Gershner, et al.
Page
of 27